The advent of artificial intelligence (AI) at the US Food and Drug Administration (FDA) is changing the complexion of the regulatory approval process for medical devices.

AI was supposed to boost drug discovery, but progress has stalled. Learn why the hype hasn’t delivered and what needs to ...

Carlsbad, California–based Carlsmed designed the Aprevo devices to match the unique anatomical and alignment needs of each ...

Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on developing innovative treatments ...

Investing.com -- Hyperfine, Inc. (NASDAQ: HYPR) stock climbed 4.6% following the announcement of promising early results from its CARE PMR study presented at the 2025 Alzheimer’s Association ...

Digital tools can help amid manpower shortage at public health institutions. Read more at straitstimes.com. Read more at ...

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our ...

Over the past decade, health insurance companies have increasingly embraced the use of artificial intelligence algorithms – ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...

From overlooked diagnostics and underused screening to AI potential and workforce gaps, these are the innovation challenges in oncology that cancer leaders told Becker’s they feel deserve more ...

Artificial intelligence is increasingly being used by insurers to approve or deny medical treatments. According to WETM, ...

Carlsmed, Inc. (Nasdaq: CARL) ('Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful completion of the first aprevo® ...